Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Other Accumulated Expenses (2019 - 2026)

Alx Oncology Holdings' Other Accumulated Expenses history spans 5 years, with the latest figure at $543000.0 for Q4 2023.

  • On a quarterly basis, Other Accumulated Expenses fell 73.51% to $543000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $543000.0, a 73.51% decrease, with the full-year FY2023 number at $543000.0, down 73.51% from a year prior.
  • Other Accumulated Expenses hit $543000.0 in Q4 2023 for Alx Oncology Holdings, up from $265000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for ALXO hit a ceiling of $2.0 million in Q4 2022 and a floor of $102000.0 in Q3 2021.
  • Historically, Other Accumulated Expenses has averaged $517750.0 across 5 years, with a median of $261500.0 in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: soared 774.51% in 2022 and later crashed 73.51% in 2023.
  • Tracing ALXO's Other Accumulated Expenses over 5 years: stood at $136000.0 in 2019, then grew by 11.03% to $151000.0 in 2020, then surged by 56.29% to $236000.0 in 2021, then skyrocketed by 768.64% to $2.0 million in 2022, then crashed by 73.51% to $543000.0 in 2023.
  • Business Quant data shows Other Accumulated Expenses for ALXO at $543000.0 in Q4 2023, $265000.0 in Q3 2023, and $1.8 million in Q2 2023.